Albany Molecular Research Inc. (AMRI), a contract research, development and manufacturing organization, has completed its previously announced acquisition by affiliates of The Carlyle Group and affiliates of GTCR LLC, two investment firms. AMRI had announced the acquisition in June 2017.

With the move, AMRI, formerly a publicly traded company, will go private. President and Chief Executive Officer William S. Marth will continue to lead AMRI.

AMRI recorded contract revenues of $560.43 million in 2016. The company has four business segments: drug-discovery services (DDS), active pharmaceutical ingredients (API), drug products (DP), and fine chemicals (FC). Its DDS segment provides services from hit identification to investigational new drug applications, including drug -ead discovery, library design and synthesis, synthetic and medicinal chemistry, in vitro biology and pharmacology, lead optimization, chemical development, drug metabolism and pharmacokinetics, analytical testing services, and small-scale commercial manufacturing. Its API segment provides pilot- to commercial-scale manufacturing of APIs, including intermediates, high-potency and controlled substances, steroids and hormones, and sterile APIs. Its DP segment provides formulation through commercial-scale production of liquid-filled and lyophilized injectable products and opthalmic formulations. Its FC segment provides laboratory- to commercial-scale synthesis of reagents and diverse compounds. As of December 31, 2016, the company had 3,085 employees.

Source: AMRI